logo-loader
viewOpen Orphan PLC

Open Orphan PLC: 'Rapidly scaling up and building out higher value, longer term contracts'

 

Proactive Research analyst Emma Ulker says Open Orphan PLC (LON:ORPH) is a world leader in the testing of vaccines and anti-viral treatments through the use of human challenge study services.

She says with its hVIVO subsidiary now integrated, it's leveraging its capabilities to the full, growing the top line and targeting near term profitability by delivering specialist pharma services across its hVIVO and Venn subsidiaries.

Click here to read Emma Ulker's latest update Open Orphan: Scaling Up, Leveraging Valuable Assets

Quick facts: Open Orphan PLC

Price: 12.75 GBX

AIM:ORPH
Market: AIM
Market Cap: £84.87 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan awarded contract from Codagenix for COVID-19 Vaccine Trial

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing that US biotech Codagenix Inc has commissioned its hVIVO arm to carry out a first-in-human trial of a nasal vaccine for coronavirus. The phase I study of 48 healthy young adults will take place...

1 week, 1 day ago

2 min read